{'fraction_non_alphanumeric': 0.03795180722891566, 'fraction_numerical': 0.03253012048192771, 'mean_word_length': 4.649659863945578, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia

Essential thrombocythaemia (ET) is a relatively common myeloproliferative disorder characterized by an elevated platelet count. As thrombopoietin (TPO) and the TPO receptor (c‐mpl) regulate platelet production in normal physiology, their role in ET was investigated. A well‐characterized cohort of 23 ET patients was evaluated and followed for 3 years. The TPO levels in these ET patients (189 ± 131 pg/ml) were the same as in normal subjects (179 ± 112 pg/ml) and TPO was not produced by ET platelets. There were 5·6 ± 5·5 TPO binding sites/ET platelet vs. 56 ± 17 TPO binding sites/normal platelet and this was associated in ET patients with normal‐sized platelet c‐mpl protein and mRNA, but a 10‐fold reduction in platelet c‐mpl mRNA. The Kd for the TPO receptor on ET platelets was 66 ± 30 pmol/l vs. 163 ± 31 pmol/l on normal platelets, but the c‐mpl cDNA had a normal nucleic acid sequence. The decreased number of ET platelet TPO receptors resulted in a fourfold decrease in the platelet‐dependent TPO clearance (0·30 ± 0·14 ml/h/109 ET platelets vs. 1·24 ± 0·38 ml/h/109 normal platelets) at a time when the platelet count in ET patients was 2·7‐fold above normal. The fourfold decrease in the TPO clearance, elevated platelet mass and resulting normal total TPO clearance explain the normal TPO levels. These results also suggest that the thrombocytosis in ET may be attributed to an alteration of the normal feedback interaction between TPO and its receptor and not as a result of any defect in the structure of TPO or c‐mpl.